Fennec's PEDMARK Shows Positive Clinical Data, Expanded Use Potential at ASCO
summarizeSummary
Fennec Pharmaceuticals announced positive clinical data for its key product, PEDMARK, from four studies presented at the 2026 ASCO Annual Meeting. The Japanese STS-J01 trial met its primary endpoint, demonstrating a significant reduction in cisplatin-induced hearing loss in pediatric patients. Real-world data also showed PEDMARK's feasibility and safety for expanded use in AYA and adult patients, without compromising anti-tumor activity. This news provides concrete evidence for broadening PEDMARK's market beyond its current pediatric indication, building on previous announcements regarding ASCO abstract acceptance.
At the time of this announcement, FENC was trading at $9.93 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $344.9M. The 52-week trading range was $5.65 to $10.45. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Wiseek News.